Successful challenge with the fully human EGFR antibody panitumumab following an infusion reaction with the chimeric EGFR antibody cetuximab

Ann Oncol. 2007 May;18(5):963-4. doi: 10.1093/annonc/mdm130.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Adult
  • Antibodies, Monoclonal / administration & dosage
  • Antibodies, Monoclonal / adverse effects*
  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents / administration & dosage
  • Antineoplastic Agents / adverse effects*
  • Cetuximab
  • Colonic Neoplasms / pathology
  • Colonic Neoplasms / therapy*
  • ErbB Receptors / immunology
  • Humans
  • Hypersensitivity / complications
  • Hypersensitivity / therapy*
  • Infusions, Intravenous
  • Male
  • Neoplasm Metastasis / drug therapy
  • Neoplasm Metastasis / pathology
  • Panitumumab
  • Treatment Outcome

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents
  • Panitumumab
  • ErbB Receptors
  • Cetuximab